Fujifilm Sonosite (TSE:4901) subsidiary VisualSonics said today it won CE Mark approval in the European Union for its Vevo MD ultra high frequency clinical ultrasound.
The Vevo MD operates at higher frequencies than conventional ultrasound systems currently on the market, Fujifilm said, and is now commercially available in the majority of the European Union countries.
“As the undisputed leader in ultra high frequency imaging systems, Fujifilm VisualSonics once again advances the field of ultrasound with the launch of the Vevo MD. We are proud to be the first to bring to market this exciting innovation that is sure to have high impact on the medical imaging community while expanding the product portfolio of FujiFilm SonoSite,” FujiFilm Sonosite CEO Masayuki Higuchi said in a press release.
In addition to the release of the Vevo MD, the company also introduced a UHF series of transducers capable over operating up to 70 MHz
“The Vevo MD allows medical professionals to see what they have never seen before—unparalleled image resolution down to 30 micrometers. This is less than half the size of a grain of sand. Imagine the great potential this technology has across unexplored applications to visualize the smallest, highly detailed anatomy in a way that has never been done before,” FujiFilm VisualSonics GM Renaud Maloberti said in prepared remarks.
“We believe this technology has a role to play in a range of clinical application areas from neonatology, vascular, musculoskeletal, dermatology, or other small parts that are within the first 3 cm of the body. We also know that there are new and interesting areas to be discovered. The Vevo MD gives us and our users the opportunity to make those discoveries together,” VisualSonics marketing director Andrew Needles said in a prepared statement.